Improving outcomes in hypertrophic cardiomyopathy (HCM) is focused on the improvement of the therapeutic strategies for patients with HCM. First it demonstrates that individual patient selection in patients with obstructive and symptomatic HCM can lead to near normal life-expectancy; but multidisciplinary decision-making is strongly advocated.
Second, further improvement and validation of current models of identification of high risk patients leads to more appropriate ICD therapy. Finally, the improvement of our understanding of genotype-phenotype relations could lead to possible therapeutic strategies in the future.

, ,
F. Zijlstra (Felix) , M. Michels (Michelle) , A.F.L. Schinkel (Arend)
Erasmus University Rotterdam
Department of Cardiology

Vriesendorp, P. (2016, September 6). Improving Outcomes in Hypertrophic Cardiomyopathy. Retrieved from